Welcome! Thank you for subscribing to the Earnings360 newsletter, your daily source for quarterly earnings news and updates.
Each morning edition contains a wrap-up of today's pre-market earnings announcements and yesterday's earnings announcements after the closing bell.
Please take a moment to confirm your subscription below so we can ensure these updates reach your inbox.
Confirm Your Subscription Here
The Earnings360 Team
Featured Story from MarketBeat.com 3 Smart Defensive Stocks for an Uneasy MarketWritten by Chris Markoch. Published 11/18/2025. 
Key Points - Despite new market highs, recession risks remain elevated due to weakening consumer credit and signs of job market stress.
- Procter & Gamble and Johnson & Johnson offer stable dividends, strong balance sheets, and catalysts that could provide upside in a downturn.
- A rotation away from AI and into Dow components could make the DIA ETF a compelling defensive play for 2025.
At one point in early November, the Dow Jones Industrial Average (DJIA) briefly topped 48,000 for the first time ever. At various points in 2025, the NASDAQ and S&P 500 have also made new all-time highs (ATHs). Despite sharp price swings, it has been a strong year to own stocks. Yet many economists, analysts, and investors remain uneasy. The market appears priced for perfection—recession risks, by many measures, are not fully priced in. The market's rally has investors feeling confident, but Whitney Tilson believes the real story is happening beneath the surface. His team's system recently flagged Robinhood before its big move — not because of headlines or hype, but because the mechanics driving today's market are shifting in ways most investors don't yet see.
Tilson says we're in the early stages of a broader reset that could widen the gap between those who adapt and those who don't. As part of Stansberry's Black Friday event, his latest research is available at the lowest price of the year, with a full breakdown of the trends he believes will shape the next phase of this market. Review everything here and claim your Black Friday access Even with broad gains, skepticism persists. The Magnificent 7 trade may have cooled off, but the market is clearly being lifted by a narrow group of names, largely tied to the AI boom. The K-Shaped Economy Concern Current economic commentary focuses on a K-shaped recovery. Higher-income consumers are navigating inflation near 3%—still above the Federal Reserve's informal 2% target but more manageable for affluent households. Lower-income consumers, however, have been under pressure for several years. Rising credit defaults, delinquent auto loans, and a recent uptick in foreclosures suggest this problem is worsening. The labor market, once the economy's strongest pillar, is beginning to show signs of strain. JPMorgan Chase & Co. (NYSE: JPM) recently lowered its estimated probability of a recession from 60% to 40% following a de-escalation in trade tensions. That reduction helps, but the risk remains material. Market Breadth Remains Narrow as Investors Chase Mega-Caps Recent data from Charles Schwab shows the percentage of S&P 500, NASDAQ, and Russell 2000 stocks trading above their 200-day moving average was slightly above 50%. That's historically low market breadth, and it's adding to investors' concerns. This isn't a reenactment of 2021, when investors piled into unprofitable SPACs in hopes of striking it rich. Today's froth is concentrated in mega-cap stocks that often have substantial cash on their balance sheets. Still, many investors worry these names are overvalued. So what's an investor to do? Below are three stocks (and one ETF) that offer the potential for asymmetric returns in an uneasy market. Procter & Gamble Has More Than a Dividend to Like Procter & Gamble Co. (NYSE: PG) is a member of the exclusive Dividend Kings club, having increased its dividend for at least 50 consecutive years—70 years in PG's case. That long dividend history makes it a staple for many income-oriented portfolios. Its current 2.8% dividend yield could look more attractive if rates fall. Additionally, the $171.53 price target implies roughly 17% upside for the stock in 2025. PG's proposed acquisition of Kenvue (NYSE: KVUE) introduces some uncertainty around near-term earnings. If the deal closes and the Tylenol-related issues abate, the first year would likely show modest EPS dilution. Over time, however, expected cost synergies between the companies should help turn that dilution into EPS accretion, supporting longer-term growth. Johnson & Johnson Doubles Down on Medtech and Oncology Growth Johnson & Johnson (NYSE: JNJ) spun off Kenvue in 2023 to refocus on medtech and pharmaceuticals. Its recent acquisition demonstrates that strategic shift. The company announced an approximately $3.5 billion acquisition of Halda Therapeutics, giving JNJ access to the clinical-stage HLD-0915 candidate. HLD-0915 is a once-daily oral therapy for prostate cancer that received fast-track designation from the U.S. Food & Drug Administration (FDA). This addition meaningfully strengthens JNJ's oncology pipeline and should make the stock more attractive to growth-oriented investors. The DIA ETF Could Benefit From a Flight to Safety Over the past five years, many investors embraced a passive "SPY and chill" strategy by investing in the SPDR S&P 500 ETF Trust (NYSEARCA: SPY). SPY may still be a sensible core holding, but with potential AI overexuberance, investors might consider the SPDR Dow Jones Industrial Average ETF Trust (NYSEARCA: DIA) as a defensive alternative. If concerns about an AI bubble mount, expect a rotation into the Dow 30's more diversified, blue-chip constituents. DIA could capture that rotation and act as an asymmetric hedge. As of this writing, DIA has about 37% institutional ownership, but it has seen net buying in seven of the last eight quarters—suggesting institutions may be quietly building a hedge against a potential slowdown in the tech trade.
| 
